Ki-67在脑膜瘤中的研究进展

Research Progress of Ki-67 in Meningioma

脑膜瘤是中枢神经系统最常见的非恶性原发性肿瘤,也是颅内最常见的非神经上皮来源肿瘤,多为良性且预后良好。但有部分患者在脑膜瘤切除术后出现肿瘤复发,最终临床结局较差。因此,准确的脑膜瘤分级和预后评估对于脑膜瘤的治疗决策至关重要。Ki-67是衡量细胞增殖的典型免疫组织化学标志物。Ki-67高表达与肿瘤分化差及预后不良显著相关,目前主要用于脑膜瘤分级及预后预测,并在脑膜瘤术前预测研究中显示出较好结果。

Meningioma is the most common non-malignant primary tumor in the central nervous system and also the most common non-neuroepithelial tumor in the brain,which is mostly benign and has a good prognosis.However,some patients experience tumor recurrence after meningioma resection,resulting in poor clinical outcomes finally.Therefore,accurate grading and prognostic evaluation of meningiomas are crucial for the treatment decision-making of meningiomas.Ki-67 is a typical immunohistochemical marker for measuring cell proliferation.The high expression of Ki-67 is significantly associated with poor tumor differentiation and poor prognosis.Currently,it is mainly used for grading and prognosis prediction of meningiomas,and has shown good results in preoperative prediction studies of meningiomas.